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        Angiogenesis, or the sprouting of new blood 
vessels from existing ones, occurs during devel-
opment and in diseases such as diabetic reti-
nopathy, endometriosis, psoriasis, rheumatoid 
arthritis, and tumor-induced angiogenesis (  1  ). 
Vascular endothelial cells rely on signaling from 
multiple integrins during the angiogenic pro-
cess (for review see reference   2  ), including the 
      v        3   and       v        5   integrins; signaling by the       v        3   
and       v        5   integrin leads to endothelial cell pro-
liferation, migration, matrix metalloprotease acti-
vation, and resistance to apoptosis (  3  ). 
  The       v        3   and       v        5   integrins are subject 
to regulation during angiogenesis. Fibroblast 
growth factor (FGF) and vascular endothelial 
growth factor (VEGF), two potent angiogenic 
factors released by tumors, induce the expres-
sion of these two integrins that collaborate with 
the FGF and VEGF receptors in angiogenic 
signaling pathways (  4  ); disrupting angiogenic 
signaling by inactivation of either integrin or 
growth factor receptor leads to endothelial cell 
apoptosis (  5  ). The integrins are often up-regu-
lated on metastatic tumors as well, leading to 
enhanced invasion, proliferation, and tumor 
survival (  6  –  9  ) by largely the same mechanisms 
operative in endothelial cells. For these reasons, 
the integrins and their regulatory mechanisms 
are attractive targets for the development of 
therapeutic drugs. Drugs that are currently being 
tested range from inhibitory integrin antibodies 
(e.g., Vitaxin [  10  ], based on the inhibitory anti-
body LM609 [  11  ]), to cyclic RGD peptides that 
interfere with ligand binding (e.g., cRGDfV, 
cilengitide, and ST1646 [ 12  –  15  ]), to peptido-
mimetics based on the RGD sequence (e.g., 
S247 [  16  ]). These inhibitors have all been shown 
to disrupt the growth of solid tumors as well 
as angiogenesis. 
  We have recently identifi  ed  a  regulatory 
mechanism by which syndecan-1 (Sdc1), a cell-
surface matrix receptor, regulates the activation 
of the       v        3   and       v        5   integrins on mammary 
carcinoma cells and fi  broblasts (  17  –  20  ). The syn-
decans are multifunctional extracellular matrix 
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  Syndecan-1 (Sdc1) is a matrix receptor shown to associate via its extracellular domain with 
the       v        3   and       v        5   integrins, potentially regulating cell adhesion, spreading, and invasion of 
cells expressing these integrins. Using Sdc1 deletion mutants expressed in human mammary 
carcinoma cells, we identifi  ed the active site within the Sdc1 core protein and derived a 
peptide inhibitor called synstatin (SSTN) that disrupts Sdc1  ’  s interaction with these integ-
rins. Because the       v        3   and       v        5   integrins are critical in angiogenesis, a process in which a 
role for Sdc1 has been uncertain, we used human vascular endothelial cells in vitro to show 
that the Sdc1 regulatory mechanism is also required for integrin activation on these cells. 
We found Sdc1 expressed in the vascular endothelium during microvessel outgrowth from 
aortic explants in vitro and in mouse mammary tumors in vivo. Moreover, we show that 
SSTN blocks angiogenesis in vitro or when delivered systemically in a mouse model of 
angiogenesis in vivo, and impairs mammary tumor growth in an orthotopic mouse tumor 
model. Thus, Sdc1 is a critical regulator of these two important integrins during angiogen-
esis and tumorigenesis, and is inhibited by the novel SSTN peptide. 
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active site between amino acids 88 and 121 in its extracellular 
domain fail to rescue (see mSdc1    67  –  121;   Fig. 1 B  ). 
  We showed previously (  20  ) that       v        3   integrin activity is 
lost in MDA-MB-231 cell adhesion/spreading assays in the 
presence of soluble, recombinant glutathione S-transferase  –
  fused Sdc1 extracellular domain (GST-S1ED; ID  50   of     3   μ  M). 
To test whether shorter peptides would mimic this activity, 
we derived a peptide spanning amino acids 82  –  130 of mSdc1 
(  Fig. 1 A  ). We call the inhibitory peptide sequence SSTN. 
  Indeed, treatment of MDA-MB-231 cells with SSTN  82-130   
blocks their spreading on VN but not FN (  Fig. 1 C  ). 
  We hypothesize that S1ED or SSTN  82-130   may compete 
for an interaction between the S1ED and the       v        3   integrin. 
To assess this, immunoprecipitations were performed using 
MDA-MB-231 cells expressing either empty vector (NEO), 
ectopic full-length mSdc1, or the mSdc1    67  –  121 deletion 
mutant that lacks the active site. Immunoblotting reveals 
that the       v        3   integrin coprecipitates with either native human 
Sdc1 (hSdc1) or ectopic mSdc1, yet fails to associate with 
the mSdc1 mutant bearing the     67  –  121 deletion (  Fig. 1 D  ). 
Coprecipitation is disrupted in the presence of either 30   μ  M 
GST-S1ED protein (using either mS1ED or hS1ED to avoid 
reactivity with the precipitating mAb) or 3   μ  M SSTN  82-130   
(which is not recognized by either precipitating mAb). 
These results suggest that these inhibitors block       v        3   integ-
rin activation by competitively displacing the integrin from 
an interaction with Sdc1. 
  To defi  ne the minimal sequence required, we tested SSTN 
peptides (0  –  100   μ  M) carrying sequential N- and C-terminal 
deletions (  Fig. 2 C  ) for their ability to block cell spreading on 
VN (  Fig. 2, A and B  ).   The minimal peptide required for full 
activity is SSTN  92-119  . Deletion of two or three residues from 
either end of this peptide either diminishes (approximately 
threefold loss in activity in SSTN  88-117  ) or completely abolishes 
(SSTN  94-119   and SSTN  88-116  ) activity. A peptide representing 
the homologous region of hSdc1, hSSTN  89-120  , is equally ef-
fective as an inhibitor (  Fig. 2 C  ), confi  rming that the active 
site is conserved between hSdc1 and mSdc1. Peptides dis-
played identical inhibitory eff  ects on B82L fi  broblasts, which 
rely solely on the       v        5   integrin for adhesion and spreading on 
VN (unpublished data) (  19  ). 
  Sdc1 regulates the       v        3   and       v        5   integrins on vascular 
endothelial cells 
  We next questioned whether the Sdc1 regulatory mechanism 
is operative on vascular endothelial cells. Human aortic 
endothelial cells (HAECs) and human dermal microvascular 
endothelial cells (HMEC-1s) express modest levels of Sdc1 
and higher levels of       v        3   and       v        5   integrins (  Fig. 3 A  ).   
Mouse aortic endothelial cells (MAECs) express higher lev-
els of Sdc1 than their human counterparts but less of the two 
integrins (  Fig. 3 A  ). 
  To determine if Sdc1 and the integrins are in a regulatory 
complex, immunoprecipitates from HMEC-1s were probed 
for the coprecipitation of       3   and       5   integrin subunits with 
Sdc1. Both integrins coprecipitate with the syndecan and 
receptors on the surface of all adherent cells (  21  –  23  ). They 
anchor to the matrix via heparan sulfate (HS) glycosaminogly-
can chains attached near the distal tips of their core proteins; 
these chains recognize   “  heparin-binding  ”   domains present 
in most matrix ligands, including fi  bronectin (FN), laminins, 
vitronectin (VN), thrombospondin, and the fi  brillar collagens 
(  21  ). In addition, mounting evidence suggests that they as-
semble with and control the signaling of other cell surface 
  receptors, including integrins. McFall et al. fi  rst described a 
  “  cell-binding domain  ”   in the extracellular domain of Sdc4 
(  24, 25  ); this site has recently been shown to regulate     1-con-
taining integrins on mesenchymal cells, although the exact 
integrin target and regulatory mechanism remain unknown 
(  26, 27  ). Recombinant Sdc2 extracellular domain alters adhe-
sion mechanisms in colon carcinoma cells, suggesting that a 
regulatory site also exists in its extracellular domain (  28, 29  ). 
More recently, we have shown that Sdc1 is necessary for acti-
vation of the       v        3   integrin on mammary carcinoma cells 
(  17, 20  ). Silencing Sdc1 expression, selective deletion of amino 
acids in its extracellular domain, or targeted competition with 
domain-specifi  c antibodies or recombinant extracellular do-
main protein disrupts integrin activation and matrix recogni-
tion necessary for cell spreading and invasion. Similar activation 
of the       v        5   integrin by Sdc1 occurs on B82L fi  broblasts, 
which rely exclusively on this integrin for attachment to VN 
and FN (  19  ). These extracellular syndecan-specifi  c regulatory 
sites are readily accessible to therapeutic drugs and may hold 
promise as targets for combating tumorigenesis and other dis-
eases in which their regulated mechanisms play a role. 
  Given the importance of the       v        3   and       v        5   integrins in 
angiogenesis, we examined the possibility that Sdc1 regulates 
these integrins on vascular endothelial cells during tumor-
induced angiogenesis. We found that Sdc1 is expressed by 
mouse and human endothelial cells in vitro, and is expressed 
during angiogenesis induced by FGF or VEGF in vitro and in 
vivo. We found that the       v        3   and       v        5   integrins associate 
with Sdc1 and that this association can be disrupted by a pep-
tide called synstatin (SSTN) that is derived from the active 
site in the Sdc1 core protein. Furthermore, SSTN is an eff  ec-
tive inhibitor of angiogenesis in vitro and in vivo, and of 
mammary carcinoma formation in nude mice. These results 
defi  ne the Sdc1 regulatory mechanism as a critical compo-
nent of the angiogenic and tumorigenic process. 
    RESULTS   
  SSTN peptide inhibits Sdc1-mediated activation of the       v        3   
integrin on mammary carcinoma cells 
  MDA-MB-231 human mammary carcinoma cells rely on 
Sdc1 for activation of the       v        3   integrin during their binding 
and spreading on VN (  17, 20  ). Integrin activity is abolished 
by silencing Sdc1 expression with human-specifi  c small inter-
fering RNA (siRNA) but can be rescued by expression of 
mouse Sdc1 (mSdc1;   Fig. 1 B  ).   Cell binding and spreading on 
FN, which utilizes the       5        1   integrin, is unaff  ected (  Fig. 1 B  ) 
(  20  ). Although native mSdc1 rescues integrin activity, dele-
tion mutants (summarized in   Fig. 1 A  ) (  20  ) lacking a putative JEM VOL. 206, March 16, 2009 
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also conducted in the presence of either 30   μ  M GST-
mS1ED or 3   μ  M SSTN  82-130  , SSTN  92-119  , or SSTN  94-119  ; 
note that none of these are recognized by the human-spe-
cifi  c mAb used for precipitation (  Fig. 3 B  ). As expected, 
both the GST-mS1ED protein (but not GST alone) and the 
in seemingly equal proportions (quantifi  ed via comparison 
to a whole-cell lysate standard curve; not depicted) sug-
gestive of a 1:1 correspondence (  Fig. 3 B  ). The       v        1   integ-
rin, which is not regulated by Sdc1 (  17, 19, 20  ), fails to 
coprecipitate (unpublished data). Immunoprecipitations were 
    Figure 1.         Derivation of SSTN peptide.   (A) Summary of     v    3   or     v    5   integrin activation in cell attachment/spreading assays by either native or mu-
tant mSdc1, mSdc4, or hSdc1 (reference   20  ). Numbers refer to mouse amino acid sequence. HS attachment sites in Sdc1 are amino acids 37, 45, and 47. 
Deletions identify a putative active site between amino acids 88  –  121; this site is contained in an SSTN peptide encompassing amino acids 82  –  130 
(SSTN  82-130  ). CD, cytoplasmic domain; GPI, glycosylphosphatidylinositol-linked lipid tail; TM, transmembrane domain. (B) mSdc1     67-121   deletion mutant 
fails to activate the     v    3   integrin. Spreading of MDA-MB-231 cells for 2 h on either VN (    v    3   dependent) or FN (    v    3   independent) after silencing of 
hSdc1 expression with human-specifi  c siRNA and rescue with either mSdc1 or mSdc1     67-121   deletion mutant. All images represent results from triplicate 
wells and three independent experiments. Bar, 50   μ  m. (C) Spreading of MDA-MB-231 cells on VN or FN in the presence or absence of 1   μ  M SSTN  82-130 .  Bar, 
50   μ  m. (D) SSTN disrupts Sdc1 coimmunoprecipitation with the     v    3   integrin. hSdc1 is immunoprecipitated (using mAb B-B4) from MDA-MB-231 cells 
transfected with empty vector (NEO), and mSdc1 is immunoprecipitated (using mAb 281.2) from cells transfected with full-length mSdc1 or the mSdc1 
deletion mutant (mSdc1     67-121  ). Immunoprecipitations were conducted in the presence or absence of GST, GST-S1ED (mS1ED if precipitating hSdc1 and 
hS1ED for mSdc1 precipitation), or SSTN  82-130.   Blots were probed for coprecipitation of     3   integrin subunit (    105 kD) using Fire   &   Ice. Note the nonspe-
cifi  c band (*) that appears in all lanes, including the nonspecifi  c IgG  1   isotype control precipitations. Sdc1 runs as a band at approximately 85 kD after 
treatment with enzymes to remove its glycosaminoglycan chains; the core protein is visualized on the blots using mAb 3G10, which detects HS attach-
ment stubs remaining on either the hSdc1 or mSdc1 core protein. Results are representative of at least three independent experiments.   694 SYNSTATIN, A NOVEL ANTIANGIOGENIC PEPTIDE   | Beauvais et al. 
for both cell types when Sdc1 expression is reduced by     90% 
(  Fig. 3 F  ). This is compared with combined treatment with 
30   μ  g/ml       v        3   and       v        5   function  –  blocking antibodies 
LM609 and P1F6 (  Fig. 3 F  ). 
  We next tested whether the SSTN peptides inhibit in-
tegrin activation on the endothelial cells. HMEC-1s were 
plated on hSdc1 antibody (mAb B-B4), to which the cells 
attach and spread (  Fig. 4 A  ).   Our previous work using car-
cinoma cells showed that Sdc1 ligation by this method leads 
to integrin activation and cell spreading (  17  ), even in the 
presence of EDTA to block potential ligand binding by the 
integrin. Indeed, the       v        3   and       v        5   integrins become acti-
vated when the cells attach to B-B4, detected by staining 
the cells with the ligand-mimetic Fab WOW-1 (  Fig. 4 A  ) 
(  30  ). However, treatment with either 0.5   μ  M SSTN  82-130   
or 30   μ  g/ml       v        3   and       v        5   integrin function  –  blocking 
antibodies (used as a comparative control) prevents both 
cell spreading and recognition by WOW-1, indicating that 
SSTN  82-130   inhibits integrin activation. A similar experiment 
was conducted using suspended human umbilical vein endo-
thelial cells (HUVECs) in which cell-surface Sdc1 is fi  rst 
decorated with hSdc1-specifi  c mAb B-A38 and then clus-
tered by addition of a secondary antibody in the presence or 
active SSTN  82-130   and SSTN  92-119   effi   ciently disrupt the Sdc1  –
  integrin interactions, whereas the inactive SSTN  94-119   is 
without eff  ect. 
  To test whether Sdc1 interacts directly with the integrins 
(  Fig. 3 C  ), GST-mS1ED immobilized on glutathione beads was 
mixed in solution with 1   μ  M purifi  ed       v        3   or       v        5   integrin 
in the presence of 10   μ  M competitive SSTN  92-119   or non-
competitive SSTN  94-119  . The purifi  ed integrins associate with 
S1ED, and their binding is competed by SSTN  92-119   but not 
by SSTN  94-119  . In addition, SSTN  92-119   prelabeled with photo-
activatable Sulfo-SBED cross-linker (see Materials and methods) 
binds and transfers biotin label to both the      and      subunits 
of purifi  ed       v        3   integrin, whereas no transfer is detected with 
SSTN  94-119   (  Fig. 3 D  ). 
  We next questioned whether the Sdc1 regulatory mecha-
nism aff  ects integrin activity on endothelial cells. Sdc1 ex-
pression was silenced in HMEC-1s using siRNA (  Fig. 3 E  , 
left), and the cells were plated on VN. Control siRNA  –  trans-
fected cells bind and spread, but the spreading is blocked by 
  >  95% if Sdc1 expression is silenced (  Fig. 3 E  , right). Quanti-
fi  cation of HMEC-1 and HAEC cell spreading (  Fig. 3 F  , left) 
or attachment (  Fig. 3 F  , right) shows that cell spreading is 
completely blocked, and cell attachment is blocked by 80% 
    Figure 2.         Identifi  cation of minimal SSTN peptide.   (A) Inhibition of MDA-MB-231 cell spreading on VN by SSTN. MDA-MB-231 cells were plated for 
2 h on VN in the presence or absence of 3   μ  M mS1ED or 0.3   μ  M SSTN  82-130 ,  SSTN 88-117 ,  SSTN 92-119  , or SSTN  94-119  . Bar, 50   μ  m. (B) Quantifi  cation of cell 
spreading over a range of SSTN concentrations. Error bars represent SEM of triplicate points in each of two independent experiments. *, P   <   0.05; **, 
P   <   0.01). (C) Summary of SSTN peptides tested and their effi  cacy as inhibitors in the     v    3  -dependent MDA-MB-231 cell spreading assay. The active 
92  –  119 sequence is underlined in the larger SSTN  82-130   sequence.   JEM VOL. 206, March 16, 2009 
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    Figure 3.         Expression of Sdc1 and       v        3   and       v        5   integrins in vascular endothelial cells.   (A)  Sdc1,     v    3 ,  or     v    5   expression on HAECs, HMEC-1s, or 
MAECs is analyzed by fl  ow cytometry. (B) SSTN competition for Sdc1 association with     v    3   and     v    5   integrins. hSdc1 is immunoprecipitated from HMEC-1s using 
mAb B-B4 in the absence or presence of 30   μ  M GST, 30   μ  M GST-S1ED, or 3   μ  M SSTN  82-130 ,  SSTN 92-119  , or SSTN  94-119  . Blots are probed for Sdc1 precipitation (   85 
kD) and for coprecipitating     3   integrin  (   105 kD) subunit using Fire   &   Ice, and     5   subunit with AB1926 (    100 kD). (C) Sdc1 associates directly with purifi  ed     v    3   
or     v    5   integrin and is competed by SSTN  92-119  . Glutathione beads bearing GST-mS1ED were incubated with purifi  ed integrin in the presence or absence of 
SSTN  92-119   and SSTN  94-119  . Integrin captured by the beads (or beads bearing GST alone) was detected on blots. Results are representative of at least three indepen-
dent experiments. (D) Cross-linking SSTN  92-119   to     v    3   integrin.  SSTN 92-119   or  SSTN 94-119   prelabeled with Sulfo-SBED, a UV photoactivatable biotin transfer reagent, 
was incubated with purifi  ed     v    3   integrin, and the transfer of the biotin label from SSTN to the     v   and     3   subunits was assessed by Western blot either with 
(X-link +) or without (X-link     ) photoactivation of the cross-linker. Results are representative of duplicate samples and at least two independent experiments. 
(E) Dependence of     v    3   and     v    5   integrin activation on Sdc1 in HMEC-1s. (left) Sdc1 expression in HMEC-1s was detected by mAb B-B4 in fl  ow cytometry with 
or without silencing expression with Sdc1-specifi  c siRNA. (right) HMEC-1s were plated on VN for 2 h with or without silencing hSdc1 expression. Bar, 50   μ  m. 
(F) Effect of Sdc1 silencing on endothelial cell attachment and spreading. Quantifi  cation of the percentage of spread HMEC-1s and HAECs (left) or attached cells 
(right) after treatment with control or hSdc1-specifi  c siRNA to silence Sdc1 expression, or compared with treating with 30   μ  g/ml     v    3   integrin and     v    5   integrin 
blocking antibodies LM609 and P1F6, respectively, versus an isotype control antibody to block integrin activity. Note that these antibody concentrations allow 
half-maximal binding. Results are representative of triplicate wells and at least two independent experiments. Data are presented as means   ±   SEM. **, P   <   0.01.    
absence of SSTN  82-130  . WOW-1 binding shows that cluster-
ing of Sdc1 activates the integrin, and this is prevented by 
the SSTN peptide (  Fig. 4 B  ). 
  Blockade of integrin activation with the SSTN peptides is 
also shown by disrupted cell attachment and spreading on 
VN. HMEC-1s are dependent on both integrins, as partial 696 SYNSTATIN, A NOVEL ANTIANGIOGENIC PEPTIDE   | Beauvais et al. 
tive SSTN  94-119   is without eff  ect even at 100   μ  M, addition of ei-
ther 5   μ  M mS1ED, 0.5   μ  M SSTN  82-130  , or 0.5   μ  M SSTN  92-119   
blocks spreading on VN as eff  ectively as (if not better than) 
spreading is observed if one integrin is blocked (e.g., LM609 to 
block       v        3  , or P1F6 to block       v        5  ), but a complete block occurs 
in the presence of both antibodies (  Fig. 4 C  ). Although the inac-
    Figure 4.         Inhibition of       v        3   and       v        5   integrin activation in HMEC-1 vascular endothelial cells by SSTN.   (A) Activation of     v    3   integrin  is 
blocked by SSTN. HMEC-1s plated for 2 h on hSdc1-specifi  c antibody B-B4 in the presence or absence of 0.5   μ  M SSTN  82-130   or 30   μ  g/ml of mAbs LM609 
and P1F6. Integrin activation is shown by integrin-dependent cell spreading and by staining with the monovalent ligand-mimetic Fab antibody WOW-1. 
Results are representative of triplicate wells and two independent experiments. Bar, 20   μ  m. (B) Integrin activation by Sdc1 clustering. Sdc1  +   HUVECs  in 
suspension were treated with mAb B-A38 to engage Sdc1 and was treated with or without secondary antibody to cluster the syndecan in the presence or 
absence of 1   μ  M SSTN  82-130 .  Quantifi  cation of WOW-1 binding via fl  ow cytometry was used to measure the levels of activated     v    3   integrin. Results are 
representative of duplicate samples and at least two independent experiments. MFI, mean fl  uorescent intensity. (C) HMEC-1 spreading on VN is dependent 
on integrins     v    3   and     v    5   and is blocked by SSTN. HMEC-1s plated on VN for 2 h were treated with 30   μ  g/ml of mAb LM609 (    v    3   blocker), 30   μ  g/ml 
of mAb P1F6 (    v    5   blocker), or both antibodies, or 5   μ  M mS1ED, or 0.5   μ  M SSTN  82-130 ,  SSTN 92-119  , or SSTN  94-119   as competitive inhibitors. The SSTN in-
hibitors were also tested on cells plated on FN as a negative control (right column). Results are representative of triplicate wells and at least two indepen-
dent experiments. Bar, 50   μ  m. (D) Quantifi  cation of cell spreading. The percentage of spread HMEC-1s and HAECs was quantifi  ed after plating for 2 h on 
VN in the presence of mS1ED or SSTN peptides. **, P   <   0.01. (E) Sdc1-negative HUVECs have activated     v    3   and     v    5   integrin but are insensitive to inhibi-
tory SSTN peptide treatment. Expression of Sdc1,     v    3  , and     v    5   are  quantifi  ed by fl  ow cytometry (left) in two isolates of HUVECs, one of which is Sdc1 
negative (Sdc1       ). The Sdc1  +   and  Sdc1       HUVECs are compared in cell spreading assays on VN, using competition with SSTN  82-130  , silencing Sdc1 expression 
with siRNA, and blocking     v    3   alone or both     v    3   and     v    5   integrins with blocking antibodies LM609 and P1F6 (right). Results are representative of trip-
licate wells and at least two independent experiments. Data are presented as means   ±   SEM. **, P   <   0.01.     JEM VOL. 206, March 16, 2009 
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to be Sdc1 positive. These same cell layers are positive for       v  , 
      3  , and       5   integrin subunits. A similar fi  nding is seen in mam-
mary tumors arising from overexpression of     N89    -catenin 
(  32  ). Although the vascularization is not as extensive as in the 
Wnt-1  –  induced tumors, there are clear thickened layers of 
activated endothelial cells that are positive for PECAM-1, 
Sdc1, and       v        3  /      v        5   integrin in these mammary tumors. 
  To test the importance of the Sdc1 regulatory mechanism 
during angiogenesis, we tested the activity of SSTN peptides in 
the in vitro mouse aortic ring outgrowth assay (  33  ) and the 
in vivo mouse corneal pocket angiogenesis model (  34  ). The 
aortic outgrowth assay was used to quantify microvessel out-
growth from segments of mouse aorta explanted to collagen 
gels in the presence of either VEGF or FGF-2, and incubated 
in the presence of either recombinant mS1ED protein or SSTN 
peptides. Microvessels are observed growing out of the aortic 
explants over 7 d in response to VEGF, and this is blocked 
by increasing concentrations of SSTN  82-130   or by an antibody 
(M9) that inhibits mouse       v  -containing integrins (  Fig. 6 A  ).   
Single cells observed to be migrating out from the explants in 
the presence of SSTN or the blocking antibody are likely to be 
fi  broblasts and pericytes. Indeed, desmin staining shows that 
pericytes line up on the PECAM-positive microvessels in the 
absence of SSTN and continue to migrate out from the ex-
plant in a disorganized fashion when SSTN prevents the out-
growth of PECAM-positive endothelial cells (  Fig. 6 B  ). 
  Quantifi  cation of vessel outgrowth shows that SSTN in-
hibits both VEGF- and FGF-stimulated outgrowth. Although 
some vessel outgrowth is observed in the absence of exoge-
nous angiogenic agents, likely caused by VEGF released by the 
pericytes growing out from the explant (  35  ), the outgrowth is 
greatly increased by supplementation with FGF-2 or VEGF 
(  Fig. 6, C and D  ). Addition of recombinant S1ED blocks 
VEGF-induced outgrowth by   >  70% at 10   μ  M and   >  95% at 
30   μ  M (  Fig. 6 C  ). FGF-induced outgrowth (  Fig. 6 D  ) requires 
slightly higher inhibitory concentrations (    30   μ  M mS1ED for 
70% inhibition). In comparison, SSTN  82-130   and SSTN  92-119   
are 10  –  30-fold more potent that mS1ED and show equivalent 
inhibition of VEGF- or FGF-induced outgrowth, displaying 
an ID  50   of     0.1   μ  M. These concentrations are nearly identical 
to the ID  50    ’  s displayed in the in vitro cell attachment and 
spreading assays with HMEC-1s and HAECs (compare with 
  Fig. 4  ) and are comparable to the eff  ects of 10   μ  g/ml of the 
function-blocking       v   integrin mAb M9, which inhibits the 
activity of both the       v        3   and       v        5   integrins (  Fig. 6  ). 
  The SSTN peptides were also tested in the in vivo corneal 
angiogenesis assay (  Fig. 7  ).   Poly(2-hydroxyethyl methacrylate) 
(Poly-HEMA) pellets containing 67 ng FGF-2 and 250 ng 
  sucralfate (used as a slow-release agent) were implanted into 
the avascular mouse cornea. After 7 d, fl  uorescent dextran was 
  injected retroorbitally to highlight the vascular system at the 
time of sacrifi  ce. Visual inspection of either the eye or the dis-
sected cornea shows signifi  cant vessel growth toward the im-
planted pellet from the margin of the cornea. To test the eff  ects 
of blocking Sdc1, SSTN peptides were delivered systemically 
via Alzet osmotic pumps (see Materials and methods). Pumps 
the combined antibody treatment (  Fig. 4 B  ). Attachment and 
spreading on FN is not aff  ected by these peptides (  Fig. 4 C  ) 
or by the integrin blocking antibodies (unpublished data). 
Quantifi  cation of these results shows that competition with 
mS1ED at 1 –  3-  μ  M concentrations reduces HMEC-1 cell spread-
ing on VN by   >  80  –  90% (  Fig. 4 D  ), with an ID  50   of     1   μ  M 
for HAECs, which are more resistant than the HMEC-1s. In 
comparison, SSTN  82-130   and SSTN  92-119   display an equivalent 
inhibitory activity when used at a 10-fold lower concentra-
tion, displaying signifi  cant inhibitory properties in the 0.1  –
  0.3-  μ  M range. As observed in   Fig. 4 C  , cell adhesion is also 
disrupted at the higher inhibitory concentrations and can be 
prevented altogether by adding increased concentrations of 
the peptides (unpublished data). 
  Lastly, the specifi  city of the SSTN peptides for this Sdc1-
regulated mechanism was demonstrated comparing HUVECs 
that are either positive or negative for Sdc1 expression. Although 
primary HUVECs do express Sdc1 (Sdc1  +  ), one isolate of 
these cells that we obtained failed to express the proteoglycan 
(Sdc1       ), as shown by fl  ow cytometry (  Fig. 4 E  , left); both the 
Sdc1  +   and Sdc1        cells express identical levels of       v        3   and 
      v        5   integrins. Somewhat surprisingly, both sets of cells 
attach and spread on VN (  Fig. 4 E  , right), both are inhibited 
by mAb LM609, and both are inhibited further by addition of 
mAbs LM609 and P1F6 to block both       v        3   and       v        5   integrins. 
Addition of SSTN  82-130   inhibits the spreading of the Sdc1  +   
HUVECs, similar to its eff  ect on HMEC-1s and HAECs, but 
is without eff  ect on the Sdc1        HUVECs. Similarly, silencing 
Sdc1 expression on the Sdc1  +   HUVECs blocks their spread-
ing, whereas the siRNA is without eff  ect on the Sdc1        cells, 
as would be expected. This suggests that an alternative activa-
tion mechanism exists in the absence of Sdc1 gene expression, 
and that the SSTN peptide is specifi  c only for the Sdc1-regu-
lated       v        3   and       v        5   activation mechanism. 
  SSTN inhibits angiogenesis in vitro and in vivo 
  As a fi  rst step in understanding a potential role for Sdc1 in 
angiogenesis in vivo, we questioned whether Sdc1 was ex-
pressed either in the endothelial lining of resting blood vessels 
(using the mouse aorta) or in microvessels arising from the 
aorta in response to angiogenic stimuli. As we found when 
examining the MAEC line in culture (  Fig. 3 A  ), both Sdc1 
and the       v        3   and       v        5   integrins are present even on the rest-
ing mouse aorta (  Fig. 5 A  ).   In addition, microvessels growing 
out from mouse aortic explants over 7 d in response to FGF-
2 stain positively for Sdc1, which appears coexpressed with 
the       v        3   and       v        5   integrins (  Fig. 5 B  ). In addition, Sdc1 ex-
pression is observed in activated endothelial cells of mouse 
tumor vasculature (  Fig. 5 C  ). Tumors derived from Wnt-1 
overexpression (  31  ) in the mammary gland show a high de-
gree of vascularization, identifi  ed as internal networks lined 
by a thick cell layer that stains intensely for Sdc1 and for 
platelet  –  endothelial cell adhesion molecule  –  1 (PECAM-1/
CD31), indicative of activated endothelium. In fact, Sdc1 ex-
pression in these cells swamps out the positive staining for 
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  We also tested SSTN peptide on male BALB/c Sdc1 
knockout mice, as it has been previously reported that angio-
genesis is not blocked in this animal (  36  ). Indeed, we found 
that Sdc1      /      mice display corneal vessel outgrowth in re-
sponse to FGF-2 (  Fig. 7 C  , right, blue bars). In addition, this 
vessel outgrowth is reduced   >  60% by circulating cRGDfV, a 
cyclic RGD inhibitory peptide specifi  c  for        v   integrins, 
compared with an inactive cRADfV peptide. This duplicates 
the extent of inhibition observed for this RGD peptide in 
other mouse models (  15, 37  ). However, the angiogenesis is 
not blocked by as much as 100   μ  M SSTN  82-130  ; this concen-
tration of SSTN  82-130   inhibits angiogenesis by 90% in a parallel 
delivering 1   μ  l/h of up to 100   μ  M SSTN  82-130   or SSTN  92-119   
achieved a nearly total block of angiogenesis, with an ID  50   of 
    3  –  10   μ  M (  Fig. 7 A  ; and   Fig. 7 C  , left). To correlate this with 
the active concentration in the plasma, we took advantage of 
rabbit polyclonal antibodies generated against mS1ED that 
  detect active SSTN on dot blots (  Fig. 7 B  ). This shows that 
SSTN accumulates to 125  –  150 nM in the blood after 1 wk of 
treatment with 10   μ  M SSTN. This correlates well with the 
ID  50   of     100 nM observed in vitro and suggests a clearance 
rate of 10  –  13 h in the plasma. In contrast, delivery of 100   μ  M 
of the inactive SSTN  88-116   or SSTN  94-119   in Alzet pumps has 
no eff  ect on vessel outgrowth (  Fig. 7 A  ; and   Fig. 7 C  , left). 
    Figure 5.         Sdc1 and the       v        3  /      v        5   integrins are coexpressed in normal and tumor vasculature.   (A) En face staining of fi  xed mouse aorta for 
mSdc1 (mAb 281.2) and mouse     v   (AB1923),     3   (AB1932), or     5   (AB1926) integrin subunits. Endothelial cells are present as cords and are identifi  ed by 
mAb 390 (anti-PECAM-1/CD31) staining. Results are representative of at least three independent experiments. Bar, 50   μ  m. (B) Sdc1 expression in aortic 
explants. Staining with mSdc1-specifi  c mAb (green) or control rat IgG and     3   or     5   integrin – specifi  c IgG (red) or control rabbit IgG in microvessels in-
duced by 30 ng/ml FGF-2 after 7 d from mouse aortic explants grown in type-I collagen gels. PECAM-1 staining of microvessels is also shown. Results are 
representative of triplicate wells and at least two independent experiments. Bar, 50   μ  m. (C) Expression of Sdc1 and integrins in tumor vasculature. 
PECAM-1, Sdc1, or     v ,     3  , or     5   integrin subunits are stained in frozen sections of spontaneous mammary tumors arising in mice because of MMTV pro-
moter  –  driven expression of ectopic Wnt-1 or    N89   -catenin (three mice each). Arrows point to identical structures in the PECAM and Sdc1 or integrin 
costained panels to orient the reader. Results are representative of at least three independent experiments. Bar, 50   μ  m.     JEM VOL. 206, March 16, 2009 
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  results in a signifi  cant reduction in tumor size relative to con-
trol mice (  Fig. 8, A and B  ). Moreover, staining the tumor 
sections for PECAM-1 or desmin shows a signifi  cant reduc-
tion in the number of tumor vessels in the SSTN-treated 
tumors; both endothelial cells and pericytes are observed, 
but in reduced numbers of vessels (  Fig. 8 C  ). Quantifi  cation 
of angiogenesis either by measuring total vessel length in 
the sections or total PECAM-1 positive staining shows an 
11-fold reduction in animals bearing pumps containing 400   μ  M 
SSTN (  Fig. 8 D  ). 
    DISCUSSION   
  Previous work described a dependence on Sdc1 for activa-
tion of the       v        3   and       v        5   integrins. This raises the question 
experiment with wild-type BALB/c mice (  Fig. 7 C  , right, 
red bars). Thus, a compensatory mechanism exists for the ac-
tivation of the       v        3   and       v        5   integrin in the Sdc1      /      mouse 
that is insensitive to the inhibitory SSTN peptide. 
  Finally, SSTN  82-130   was tested in an in vivo orthotopic 
tumor model (  Fig. 8  ).   MDA-MB-231 human mammary car-
cinoma cells were injected subcutaneously into female, athy-
mic BALB/c nude mice. Palpable tumors were allowed to 
form for 1 wk after injection, at which time Alzet pumps 
delivering 0.25   μ  l/h of either PBS alone (control) or SSTN  82-
130   were implanted. Tumor growth was monitored for an 
additional 4 wk before sacrifi  ce. Treatment with 120   μ  M 
(0.37   ±   0.02   μ  M in the serum; not depicted) or 400   μ  M 
(1.87   ±   0.06   μ  M in the serum; not depicted) SSTN  82-130   
    Figure 6.         SSTN blocks microvessel outgrowth from mouse aortic explants.   (A) Blockade of VEGF-induced outgrowth by SSTN or     v   integrin  block-
ing antibody. Aortic explants to type-I collagen are treated with 50 ng/ml VEGF for 7 d in the presence of 0, 0.1, 0.3, and 1   μ M  SSTN 82-130   or  10   μ g/ml     v  
blocking antibody M9 or a mouse IgG control. Arrows denote microvessels. Insets show full aortic ring with dashed box to identify the magnifi  ed area 
shown. Bar, 0.5 mm. (B) Outgrowth of pericytes and endothelial cells. Aortic rings grown as in A in the presence of SSTN  94-119   (inactive) or SSTN  92-119   (ac-
tive) are stained with rat anti  –  PECAM-1 (or nonspecifi  c rat IgG) to mark endothelial cells, or mouse anti-desmin (or nonspecifi  c mouse IgG) to identify 
pericytes. Note that SSTN affects endothelial but not pericyte outgrowth. Bar, 50   μ  m. (C and D) Quantifi  cation of total microvessel outgrowth in VEGF-
treated (C) and FGF-treated (D) rings. The total microvessel outgrowth is compared for rings treated with 50 ng/ml VEGF or 30 ng/ml FGF. Each bar repre-
sents the total microvessel outgrowth per explant for six explants (  ±  SD). Rings were incubated in medium containing either no addition, mouse S1ED, 
SSTN peptides, mAb M9, or control mouse IgG. Results are representative of at least three independent experiments. **, P   <   0.01.   700 SYNSTATIN, A NOVEL ANTIANGIOGENIC PEPTIDE   | Beauvais et al. 
of whether this regulatory mechanism exists on the vascular 
endothelium during angiogenesis. Although expression of 
Sdc1 in the vascular endothelium has not been studied exten-
sively, several reports indicate that it is expressed in the endo-
thelium of newly formed vessels in wound granulation tissue 
(  38  –  41  ) and the endothelial lining of intramyocardial blood 
vessels in the rat heart (  42  ); however, no expression is seen in 
blood vessels in unwounded skin (  39  ) nor in the normal rab-
bit aorta (  43  ), suggesting that its expression may be regulated, 
perhaps by ephrin signaling (  44  ). A role in angiogenesis, 
however, is seemingly cast in doubt by the fi  nding that an-
giogenesis is not impeded in the Sdc1-null mouse (  36  ). 
  Our fi  ndings suggest that Sdc1 is indeed expressed in the 
vascular endothelium and that its core protein has an impor-
tant regulatory role during the angiogenic process. It is de-
tected, along with the       v        3   and       v        5   integrins, in cultured 
MAECs, in resting mouse aorta, and in angiogenic aortic mi-
crovessels in vitro and tumor vasculature in vivo. Although 
we have not investigated directly whether or not Sdc1 ex-
pression is up-regulated during angiogenesis, it does display 
intense staining in the endothelial cells undergoing angiogen-
esis in the aortic ring outgrowth assay and in mammary tumors. 
Up-regulated expression of Sdc1 would mimic that of the 
      v        3   integrin, which displays low or nonexistent expression 
in most adult tissues and is dramatically up-regulated in the 
vascular endothelium during angiogenesis (  45  –  47  ). Most im-
portantly, blocking Sdc1 expression or competitively block-
ing its interaction with these integrins using SSTN serves to 
inactivate the integrins and block endothelial cell attachment, 
spreading, and invasion/outgrowth in vitro, as well as angio-
genesis and tumor growth in vivo. The regulatory mecha-
nism remains unknown, but it appears to rely on a direct 
interaction between the integrins and Sdc1. 
  Interestingly, our fi  ndings do confi  rm the ability of the 
Sdc1-null mouse to mount a seemingly normal angiogenic 
response, a response that appears dependent on the       v        3   and 
      v        5   integrins despite the absence of Sdc1. This fi  nding is 
    Figure 7.         SSTN blocks FGF-induced corneal angiogenesis in vivo.  
(A) Angiogenic outgrowth in response to FGF. 0.125   μ  l of Poly-HEMA 
pellets (P in the images) containing 67 ng FGF-2 and 250 ng sucralfate 
were implanted in the avascular mouse cornea for 7 d. Alzet osmotic 
pumps were implanted subcutaneously on the backs of the animals and 
deliver 1   μ  l/h PBS or PBS plus 30   μ  M SSTN  82-130 ,  SSTN 92-119  , or SSTN  94-119 . 
Fluorescent dextran is injected intravenously 1  –  2 min before sacrifi  ce, 
and angiogenesis is imaged either in the intact eye or by fl  uorescence of 
blood vessels in the dissected cornea (insets). Vessels in the iris can be 
observed but can be distinguished from angiogenesis in the cornea. 
Results are representative of at least six mice per treatment condition. 
The experiment was repeated independently three times. Bars, 1 mm. 
(B) SSTN  82-130   concentration in the serum. 11   μ  M SSTN  82-130   was  spotted 
in triplicate on nitrocellulose with threefold dilutions, detected with Sdc1 
polyclonal rabbit antibody (left), and compared with undiluted mouse 
serum derived from mice treated with 30, 10, 3, or 0   μ  M SSTN  82-130   in  PBS 
(middle). The estimated concentration of SSTN in the serum is plotted 
versus its starting concentration in the pump (right). Data are representa-
tive of three independent experiments. (C) Quantifi  cation of corneal 
angiogenesis in wild-type and Sdc1-null (Sdc1     /    ) mice. Mean total ves-
sel outgrowth in the presence or absence of SSTN (concentration in the 
pump is shown) is quantifi  ed and expressed relative to the PBS control 
set at 100% (  ±  SD). Wild-type and Sdc1     /     mice (six mice per data point 
for each cohort from three independent experiments) were directly com-
pared using treatments of 100   μ  M SSTN  82-130  . The Sdc1     /     mice  (three 
mice per data point for one experiment) were also treated with 22.7 mM 
    v   integrin – specifi  c cRGDfV inhibitory peptide or inactive cRADfV pep-
tide. Data are presented as means   ±   SEM. *, P   <   0.05; **, P   <   0.01.     
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matched by an isolate of HUVECs that are also Sdc1 nega-
tive. They display active       v        3   and       v        5   integrins, but unlike 
their Sdc1-positive counterparts, they are not dependent on 
Sdc1 and are unaff  ected by SSTN. In these Sdc1-negative 
cells (and in the Sdc1-null mice), integrin activation presum-
ably occurs via a compensatory mechanism that is activated in 
the absence of Sdc1 gene expression. This not only explains 
why angiogenesis is observed in the Sdc1-null mouse, but it 
also provides a strong argument for the specifi  city of the 
SSTN peptide. That is, the peptide appears to compete for a 
specifi  c interaction of Sdc1 with these integrins that is essen-
tial for their activation on Sdc1-expressing cells. If this mech-
anism is absent, the peptide has no apparent off  -target eff  ects 
even at concentrations up to 100-fold greater than its ID  50  . 
  Although the mechanisms of integrin activation have re-
ceived considerable scrutiny, especially during processes such 
as platelet activation and in angiogenesis, the reliance of the 
      v        3   and       v        5   integrins on Sdc1 during angiogenesis has not 
been appreciated until now. The       v        3   integrin has been shown 
previously to associate with other membrane proteins, with 
some leading to enhanced activation of the integrin (  48  ). Inte-
grin-associated protein (also known as CD47) presents an in-
triguing comparison to Sdc1 in that it associates with the       IIb        3   
and       v        3   integrins via its extracellular domain, and this inter-
action alone is suffi   cient to activate these integrins (  49, 50  ). 
  The activation of an integrin typically refers to a confor-
mation change that dramatically increases ligand binding af-
fi  nity, and the       IIb        3   and       v        3   integrins have been used as 
models to begin to understand the activation mechanism. 
It proceeds through two or more activation states, each result-
ing in a conformational change in the integrin  ’  s extracellular 
domain in response to intracellular signals and extracellular 
ligand binding (  51  –  55  ). In a current model for       v        3   activa-
tion, the inactive integrin is in a bent confi  guration and opens 
like a switchblade when activated (  56  ). This occurs in response 
to talin binding to the       3   integrin cytoplasmic domain and 
breaking of the salt bridge that maintains the inactive confor-
mation (  57, 58  ). However, it is also enhanced by oligomer-
ization of the integrin subunits within the plane of the plasma 
membrane (  59  ), and by extracellular interactions with matrix 
ligands and/or other membrane proteins (  48  ). 
  Our data now suggest that the active conformation of the 
      v        3   and       v        5   integrins is favored by their direct association 
with Sdc1. The integrins are activated by plating endothelial 
cells on Sdc1 antibody, or by antibody-induced clustering of 
Sdc1 on suspended endothelial cells, as shown in this study by 
the binding of the ligand-mimetic Fab WOW-1; this has also 
been shown with carcinoma cells (  20  ). The activation that 
  occurs when Sdc1 is engaged by antibody is not blocked by 
depletion of divalent cations that are otherwise necessary for 
    Figure 8.         Inhibition of tumor growth by SSTN.   (A) Effects of SSTN 
on tumor growth. Isolated 5-wk-old tumors from female BALB/c nude 
mice bearing Alzet pumps delivering PBS or PBS plus 400   μ  M SSTN  82-130 . 
(B) Quantifi  cation of tumor growth over time. Alzet pumps containing 
PBS, or PBS with 120   μ  M or 400   μ  M SSTN  82-130   were implanted on the 
fl  ank of nude mice with 1-wk-old subcutaneous MDA-MB-231 cell tu-
mors (arrow and baseline tumor size). Tumor size was measured at 
weekly intervals for 4 wk of each ensuing treatment. **, P   <   0.01. 
(C) Detection of tumor vasculature in frozen OCT-embedded sections. 
Sections are stained with anti  –  PECAM-1 (mAb MEC 13.3) or nonspecifi  c rat 
IgG2A and Alexa Fluor 488  –  conjugated goat anti  –  rat secondary antibody 
to detect endothelial cells, and anti-desmin or nonspecifi  c mouse IgG1 
and Alexa Fluor 546  –  conjugated secondary antibody to detect pericytes. 
Bars, 50   μ  m. (D) Quantifi  cation of total PECAM-positive vessels. Relative 
angiogenesis was quantifi  ed by totaling either vessel length (left) or total 
PECAM-1 staining intensity (right) in frozen sections of tumors from 
mice treated with or without SSTN  82-130  . Data are from two independent 
experiments with a minimum of six mice per data point in each, and are 
presented as means   ±   SEM. **, P   <   0.01.     
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Control, Atlanta, GA) and T.J. Lawley (Emory University, Atlanta, GA) 
(  67  ). HUVECs were obtained from Cambrex Life Sciences Corp. Human 
endothelial cells were cultured in MCDB-131 (Invitrogen) medium supple-
mented with 5 mM   l-  glutamine, 20 mM NaHCO  3   (Sigma-Aldrich), 10 ng/ml 
epidermal growth factor, 1   μ  g/ml hydrocortisone, bovine brain extract with 
heparin and antibiotics (SingleQuot kit; Cambrex Life Sciences Corp.), and 
15% FBS (Gemini Bio-Products). 
  Cell attachment and spreading assay.     Cell attachment and spreading as-
says on Sdc1-specifi  c antibody or VN and silencing of Sdc1 expression by 
siRNA were conducted as previously described (  19, 20  ).   Silencer   control 
siRNAs (Applera Corporation) were use for control siRNA transfections. 
Images were acquired using an objective (PlanFluor 10  ×   [0.5 NA], PlanApo 
20  ×   [0.75 NA], or PlanApo 63  ×   [1.4 NA]; Nikon) on a microscope (Micro-
phot-FX; Nikon) equipped with a cooled charge-coupled device camera 
system (Image-Point; Nikon). 
  Construction of mSdc1 mutant.     The mSdc1      67-121   mutant was con-
structed by digesting full-length mSdc1 cDNA (pcDNA3; provided by 
R. Sanderson, University of Alabama at Birmingham, Birmingham, AL) 
with BmgBI and BstEII. The BstEII overhang was then fi  lled in using the 
Klenow DNA polymerase fragment (Promega) and the vector then blunt-
end ligated using T4 DNA ligase (New England Biolabs, Inc.). The mutant 
was transfected into MDA-MB-231 cells using LipofectAMINE PLUS 
(Invitrogen) and 10   μ  g of plasmid, in accordance with the manufacturer  ’  s 
instructions. A stable population (100  –  300 colonies) was selected in 1.5 
mg/ml G418 (EMD) and comparatively sorted against cells expressing full-
length mSdc1 for equal expression levels by fl  ow cytometry using mAb 
281.2 under sterile conditions on a triple-laser FACSVantage SE equipped 
with a FACSDiva digital electronics analyzer (BD). 
  Flow cytometry.     Cells were scanned at the University of Wisconsin Com-
prehensive Cancer Center Flow Cytometry Facility using a benchtop cytom-
eter (FACSCalibur; BD Biosciences). For cell-surface staining of Sdc1 and/or 
integrins, cells were lifted in Tris-buff  ered saline (TBS) containing 5mM 
EDTA (TES), washed in HEPES-buff  ered DMEM (Hb-DME) containing 
10% serum, incubated for 1 h on ice with 1   μ  g of primary antibody per 5   ×   
10  5   cells, washed, and counterstained with Alexa Fluor 488  –  conjugated sec-
ondary antibodies (Invitrogen). Cell scatter and propidium iodide (1   μ  g per 
sample; Sigma-Aldrich) staining profi  les were used to gate live, single-cell 
events for data analysis. For WOW1 Fab staining (i.e., detection of activated 
      v        3   integrin), HUVECs were lifted in TES and washed in serum-free 
  medium (Hb-DME containing 0.1% heat-denatured BSA [hdBSA]); this 
medium was used for all washes and incubations that follow unless otherwise 
specifi  ed. To cluster Sdc1, suspended cells were incubated with 1   μ  g/ml of 
mAb B-A38 per 5   ×   10  5   cells (or mIgG1 as an isotype control) for 15 min at 
37  °  C, washed, and incubated with 5   μ  g/ml goat anti  –  mouse IgG secondary 
antibody (Jackson ImmunoResearch Laboratories) for an additional 15 min. 
Cells were washed and blocked for 15 min in serum-free medium containing 
1% hdBSA and a 1:100 dilution of monovalent Fab fragment of goat anti  –
  mouse IgG. Cells were washed with a stoichiometric excess of serum-free 
medium and incubated with WOW-1 Fab (1:4 dilution) for 30 min at 37  °  C 
in the presence or absence of 1   μ  M SSTN  82-130  . Cells were washed with se-
rum-free medium, fi  xed in 4% paraformaldehyde (PFA) for 30 min, and 
quenched in 0.1 M glycine (in PBS) for 15 min. Cells were then counter-
stained with 10   μ  g/ml Alexa Fluor 488  –  conjugated goat anti  –  mouse IgG 
secondary antibody (Invitrogen) before scanning. Mean fl  uorescent intensity 
of triplicate samples was used as a measure of activated       v        3   integrin. 
  Immunoprecipitations.     mSdc1 and hSdc1 were immunoprecipitated using 
mAbs 281.2 and B-B4, respectively. 3  –  5   ×   10  6   cells per milliliter were washed 
and lysed in buff  er containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 
10 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, and a 1:100 dilu-
tion of protease inhibitor cocktail set III (EMD) for 20 min on ice. Insoluble 
cell debris was removed by centrifugation at 20,000   g   for 15 min at 4  °  C. Cell 
  ligand binding by the integrin, indicating that Sdc1 is en-
gaged as a membrane coreceptor, not as a ligand. The fact that 
WOW-1 is a monovalent Fab indicates that the activation is a 
true increase in integrin affi   nity rather than increased avidity. 
As we now show that the syndecan and       v        3   and/or       v        5   
  integrins form a complex, likely via lateral interactions of their 
extracellular domains, it seems apparent that clustering Sdc1 
leads to clustering of the integrins as well. It is possible that the 
clustering brings together kinases associated either with the 
  integrin or the Sdc1, initiating kinase transphosphorylation 
and activation of signaling pathways that activate the integrin 
through talin. In vivo, clustering would be envisioned to take 
place when Sdc1 engages the heparin-binding domains of mul-
tivalent matrix ligands. SSTN appears to inhibit tumorigenesis 
and angiogenesis by displacing Sdc1 from the integrins and, 
thus, blocking their activation during this clustering event. 
  MATERIALS AND METHODS 
  Materials.     Sdc1-specifi  c antibodies used were mouse mAbs B-B4 and B-
A38 (hSdc1; AbD Serotec) and rat mAb 281.2 (mSdc1) (  60  ). Rabbit poly-
clonal antibodies against recombinant mS1ED were affi   nity  purifi  ed  as 
previously described (  20  ) and used to detect SSTN. Mouse mAb 3G10, 
which specifi  cally recognizes terminal unsaturated uronic acid residues that 
remain on the core protein after treatment with heparin lyases (  61  ), was used 
for simultaneous detection of mSdc1 and hSdc1 on Western blots. Integrin 
antibodies include the polyclonal antibodies AB1923, AB1932, and AB1926 
(against       v  ,       3  , and       5  , respectively; Millipore) and mAb N29 (used for West-
ern blotting for       1  ; Millipore); blocking mAbs P1F6 and M9 (for       v        5   
and       v  , respectively; Millipore), LM609 (for       v        3  ; courtesy of D. Cheresh, 
University of California, San Diego, La Jolla, CA, and the Scripps Research 
Institute, La Jolla, CA); and   “  Fire   &   Ice  ”   (rabbit anti-      3  ; courtesy of 
P. Newman, Blood Research Institute, Blood Center of Southeastern 
Wisconsin, Milwaukee, WI). Mouse       v        5   ALULA function-blocking mAb 
was provided courtesy of D. Sheppard (University of California, San Francisco, 
San Francisco, CA). WOW-1, a ligand-mimetic Fab that serves as an   “  activation 
sensor  ”   for       v        3  , was provided courtesy of S. Shattil (University of California, 
San Diego, La Jolla, CA) (  30  ). Rat mAbs MEC 13.3 (BD) or 390 (Millipore) 
against mouse CD31/PECAM-1 were used to identify endothelial cells. 
Mouse mAb D33 (Dako) against desmin was used to identify pericytes. 
  Mouse mammary tumors were provided by C. Alexander (University 
of Wisconsin-Madison, Madison, WI); tumors were from mice overexpress-
ing Wnt-1 under control of the MMTV-LTR (  31, 62  ) or from FVB 
MMTV  –      N89    -catenin transgenic mice (  63  ). Tumors were embedded in 
optimum cutting temperature (OCT) compound (VWR) and frozen sec-
tions were prepared for staining. 
  The SSTN peptides (80  –  90% pure) were purchased from GenScript 
Corporation. They are based on the mSdc1 sequence. Recombinant mS1ED 
fusion protein was prepared as previously described (  20  ). 
  Type-I collagen was purifi  ed from rat tail tendons (  64  ), solubilized in 
0.1 M acetic acid, and dialyzed against 0.1  ×   DMEM (no serum) at pH 4 to 
remove the acetic acid. VN was purifi  ed from human plasma using a previ-
ously described method (  65  ). 
  Cell culture.     All cell lines were cultured at 37  °  C in 92.5% air/7.5% CO  2  . 
MDA-MB-231 human mammary carcinoma cells and MAECs were grown 
in DMEM (Thermo Fisher Scientifi  c) supplemented with 10% FCS (Thermo 
Fisher Scientifi  c), 4 mM   l-  glutamine (Sigma-Aldrich), and 100 U/ml peni-
cillin and 100   μ  g/ml streptomycin (Invitrogen). MAECs and HAECs were 
provided by R. Auerbach (University of Wisconsin-Madison, Madison, 
WI). These are spontaneously immortalized cell lines identifi  ed as endothe-
lial by phenotypic markers (  66  ). SV40-T immortalized HMEC-1s were de-
veloped and provided by E.W. Ades and F.J. Candal (Center for Disease JEM VOL. 206, March 16, 2009 
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After 7 d, 0.1 ml FITC-dextran (2,000,000 mol wt; Sigma-Aldrich) was retro-
orbitally injected into each mouse before sacrifi  ce, and corneas were removed 
and fi  xed in 4% PFA for imaging. Total vessel outgrowth from the limbic 
vessel at the cornea margin was summed for each mouse using Metamorph 
software. Immunofl  uorescent images were acquired using a PlanFluor 4  ×   
(0.45 NA) objective and a CoolSnap ES camera on an Eclipse TE2000U 
microscopy system. Digital images were acquired using a SMZ1500 dissect-
ing microscope and a CoolPix E5000 digital camera. 
  Subcutaneous tumors.     Under asceptic conditions, 5   ×   10  6   MDA-MB-
231 human mammary carcinoma cells (0.2 ml vol) were injected subcutane-
ously in the right rear fl  ank of 6  –  8-wk-old female, athymic BALB/c nude 
mice (Taconic) using a 3-ml sterile syringe and a 26-gauge needle. Palpable 
tumors were allowed to form for 1 wk after injection, at which time each 
animal was surgically implanted with an Alzet osmotic pump (0.25   μ  l/h) 
containing either PBS (control) or PBS plus SSTN  82-130   peptide (either 
120 or 400   μ  M). Tumor growth was monitored for an additional 4 wk by 
weekly examination and caliper measurements. At 5 wk after injection, the 
mice were humanely sacrifi  ced and tumors/serum were harvested. 
  5  –  8-  μ  m serial sections cut from frozen, OCT-embedded tumors 
were periodate-lysine-paraformaldehyde fi  xed, quenched in 0.05% NaBH  4   
  followed by 0.1M glycine, and permeabilized/blocked in IHC buff  er (0.02% 
NaN3, 0.1% BSA, 0.2% Triton X-100, and 0.05% Tween 20 in PBS) con-
taining 10% goat serum. Sections were stained with rat anti  –  mouse PECAM-
1/CD31 mAb MEC 13.3 (1:25 dilution in IHC buff   er) and/or mouse 
anti-desmin (used neat) followed by Alexa Fluor 488  –  conjugated goat anti  –
  rat/mouse secondary antibody. Images were acquired using a PlanFluor 
40  ×   objective (1.3 NA; Nikon) and a CoolSnap ES camera on an Eclipse 
TE2000U microscopy system. Mean vessel length and PECAM-1 staining 
intensity were calculated across six representative fi  elds for each cohort (i.e., 
control vs. SSTN-treated mice) using Metamorph software. 
  Dot blots.     SSTN serum levels were calculated by dot blotting using affi   n-
ity-purifi  ed, rabbit polyclonal anti-S1ED antibody. In brief, mouse serum 
collected from SSTN-treated and control mice was pooled and heated at 
65  °  C for 20  –  30 min (to inactivate endogenous AP activity), and 200   μ  l was 
spotted in triplicate on 0.2   μ  m nitrocellulose (Bio-Rad Laboratories) using a 
vacuum (Minifold Dot-Blot System; Schleicher   &   Schuell). After washing, 
the membrane was fi  xed in 0.25% glutaraldehyde for 30 min, blocked in 
TBS containing 6% BSA for 2 h at 4  °  C, and then probed using 1   μ  g/ml 
anti-S1ED antibody followed by AP-conjugated donkey anti  –  rabbit second-
ary antibody (1:5,000 dilution). Immunoreactive wells were visualized using 
ECF reagent and scanned on a Storm PhosphoImager. SSTN levels were 
calculated using Image Quant software (GE Healthcare) by comparison 
against a standard curve (i.e., 0  –  18   μ  M SSTN-spiked, heat-inactivated serum 
collected from control mice) spotted on the same blot. 
  Statistical analyses.     Statistical analyses using a two-tailed Student  ’  s   t   test 
were performed using Prism software (version 5; GraphPad Software, Inc.). 
Data that satisfy confi  dence levels of P   <   0.05 or 0.01 are noted. Data are 
presented as means   ±   SEM, unless otherwise noted. 
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lysates (2-mg input determined by BCA assay per reaction; Thermo Fisher 
Scientifi  c) were precleared using 50   μ  g/ml of isotype-matched IgG (rat IgG2A 
for 281.2 and mouse IgG1 for B-B4) and 100   μ  l of GammaBind Sepharose 
(50:50 bead/lysis buff  er slurry; GE Healthcare). Precleared lysates were incu-
bated at 4  °  C overnight with 10   μ  g/ml of anti-syndecan antibody. For compe-
tition experiments, 30   μ  M GST (negative control), 30   μ  M GST-S1ED, or 
3   μ  M SSTN was added to the precleared lysates in conjunction with anti-Sdc1 
antibody. Immune complexes were precipitated with GammaBind Sepharose, 
pelleted, washed, and incubated in 50   μ  l of heparitinase buff  er (50 mM Hepes, 
50 mM NaOAc, 150 mM NaCl, and 5 mM CaCl  2   [pH 6.5]) containing 
2.4   ×   10      3   IU/ml heparitinase (IBEX Technologies, Inc.) and 0.1 conventional 
U/ml of chondroitin ABC lysase (ICN Biochemicals) for 4 h at 37  °  C (with 
fresh enzymes added after 2 h) to remove glycosaminoglycan side chains from 
the immunoprecipitated syndecan. For precipitations using purifi  ed compo-
nents, GST or GST-S1ED protein was immobilized to glutathione agarose 
beads (GE Healthcare) and incubated with either purifi  ed       v        3   or       v        5   integ-
rin (U.S. Biological) in the presence of either competitive SSTN  92-119   or non-
competitive SSTN  94-119   peptide in sterile PBS containing the protease inhibitor 
cocktail for 4 h at 4  °  C. The samples were pelleted and washed in sterile PBS. 
In biotin label transfer assays, SSTN   “  bait  ”   (active peptide 92  –  119 or inactive 
peptide 94  –  119) was labeled with Sulfo-SBED Biotin (Thermo Fisher Scien-
tifi  c) in accordance with the manufacturer  ’  s instructions and incubated with 
purifi  ed       v        3   integrin   “  prey  ”   protein in solution. The SBED conjugate was 
photoactivated with UV light (365 nm at 5 cm for 15 min) to cross-link the 
bait  –  prey complexes. After reversal of the cross-links with dithiothreitol, bio-
tin-labeled prey protein was captured using monomeric avidin agarose beads 
(Thermo Fisher Scientifi  c). All samples were extracted in Laemmli sample 
buff  er (  68  ) and resolved by electrophoresis on a 7.5% Laemmli gel, transferred 
to ImmobilonP, and probed with alkaline phosphatase (AP)  –  conjugated strep-
tavidin alone, or 10   μ  g/ml rabbit anti-      3   Fire   &   Ice, rabbit polyclonal anti-      5   
integrin (1:1,000), 10   μ  g/ml mouse anti  –  human       v   mAb 3F12 (courtesy of S. 
Blystone, State University of New York Upstate Medical University, Syra-
cuse, NY), or 1   μ  g/ml polyclonal anti  –  mouse S1ED or mAb B-A38 antibody 
followed by an AP-conjugated secondary. Visualization of immunoreactive 
bands was performed using ECF reagent (GE Healthcare) and scanned on a 
Storm PhosphoImager (GE Healthcare). 
  Aortic ring outgrowth assay.     All animal experiments were approved by 
the University of Wisconsin Institutional Animal Care and Use Committee. 
Mouse aortic ring outgrowth assays were conducted as in Masson et al. (  33  ). 
The thoracic aortae from female BALB/c mice were cut into 1-mm segments 
and placed in 1.6-mg/ml collagen gels containing MCDB-131 endothelial 
cell growth medium (Invitrogen) and fresh 2.5% mouse serum, 100 U/ml 
penicillin, and 100   μ  g/ml streptomycin. Media containing 30 ng/ml FGF-2 
(PeproTech) or 50 ng/ml VEGF (PeproTech) and recombinant mS1ED 
or SSTN peptide was changed every 2 d for the duration of the experiment 
(7 d). Total vessel outgrowth was summed for each ring using Metamorph 
software (version 6.1; MDS Analytical Technologies). Immunofl  uorescent 
images were acquired using a PlanApo 20  ×   (0.75 NA) objective and a camera 
(CoolSnap ES; Roper Scientifi  c) on a microscopy system (Eclipse TE2000U; 
Nikon). Digital images were acquired using a dissecting microscope (SMZ1500; 
Nikon) and a digital camera (CoolPix E5000; Nikon). 
  Corneal angiogenesis assay.     For corneal angiogenesis, pellets were cre-
ated using 3 vol Poly-HEMA (Sigma-Aldrich) in 95% ethanol, and 1 vol 
each of sucralfate (100   μ  g/ml in PBS; Sigma-Aldrich), FGF-2 (3.2 mg/ml in 
PBS; PeproTech), and PBS. The solution was rapidly mixed, and 0.5-  μ  l 
drops were allowed to dry for 1 h at 4  °  C before being cut into four equal 
0.125-  μ  l sections for implantation into corneal pockets created in anesthe-
tized mice using a 1.5-mm microdissecting knife (Roboz Surgical Instru-
ment Company, Inc.). Osmotic pumps (model 2004; Alzet Osmotic Pumps) 
delivering 1   μ  l/h containing PBS or PBS with a range of SSTN concentra-
tions from 0  –  100   μ  M, or PBS containing 22.7 mM cRGDfV or cRADfV 
peptide (Enzo Life Sciences, Inc.), reconstituted in a 50:50 DMSO/double-
distilled H  2  O solution, were implanted immediately after pellet implantation. 704 SYNSTATIN, A NOVEL ANTIANGIOGENIC PEPTIDE   | Beauvais et al. 
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